The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The safety and efficacy of CC-95251 in combination with rituximab for R/R NHL
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the safety and efficacy of CC-95251, a novel monoclonal antibody targeting SIRPα, for the treatment of relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Dr Strati first explains the advantages of targeting SIRPα, and then goes on to discuss the interim results of a trial evaluating the safety and efficacy of this agent in combination with rituximab for patients with R/R NHL (NCT03783403). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Advisory Board/Consultancy: Roche Genentech, Hutchinson MediPharma, ADC Therapeutic, TG Therapeutics, Incyte Morphosis, Kite Gilead
Research Support: Astrazeneca Acerta, ADC Therapeutics, Sobi Pharmaceutics, ALX Oncology
